Body mass index and cancer risk among Chinese patients with type 2 diabetes mellitus. by Xu, Hui-Lin et al.
UCLA
UCLA Previously Published Works
Title
Body mass index and cancer risk among Chinese patients with type 2 diabetes mellitus.
Permalink
https://escholarship.org/uc/item/2f7985vq
Journal
BMC cancer, 18(1)
ISSN
1471-2407
Authors
Xu, Hui-Lin
Zhang, Min-Lu
Yan, Yu-Jie
et al.
Publication Date
2018-08-06
DOI
10.1186/s12885-018-4675-0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE Open Access
Body mass index and cancer risk among
Chinese patients with type 2 diabetes
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Nai-qing Zhao1, Wang-hong Xu1,5* and Guo-you Qin1,5,6*
Abstract
Background: Obesity and diabetes are two risk factors for cancer. To evaluate the association of body mass index
(BMI) with cancer risk in diabetic patients may improve current understanding of potential mechanisms.
Methods: A retrospective cohort study was conducted in 51,004 newly diagnosed T2DM patients derived from an
electronic health record (EHR) database of Minhang district in Shanghai, China. Incident cancer cases and all-cause
deaths occurred before September 30, 2015 were identified by linking with the Shanghai Cancer Registry and the
Shanghai Vital Statistics. To examine the potential non-linear and linear relationships of BMI and cancer risk, Cox
proportional hazard models with and without restricted cubic spline functions were used, respectively.
Results: A non-linear association was observed between BMI and overall cancer incidence in men younger than
60 years old (p for non-linearity = 0.009). Compared with those having BMI of 25.0 kg/m2, the cancer risk increased
in those with either lower or higher BMI. In women older than 60 years old, linear dose-response relationships were
observed between BMI and the risk of both overall cancer and breast cancer. As each unit increase in BMI, the
overall cancer risks elevated by 3% (95%CI: 1–5%) and the breast cancer risks increased by 7% (95%CI: 1–13%). No
significant association was observed between BMI and other common cancer sites.
Conclusions: Our results show that the effect of BMI on cancer risk in Chinese patients with T2DM may vary by
gender, age and cancer subtypes, suggesting different underlying biological mechanisms.
Keywords: Body mass index, Retrospective cohort study, Type 2 diabetes mellitus, Cancer incidence
Background
The associations of obesity [1–4] and diabetes [5, 6] with
cancer risks have recently been drawing much attention,
mainly due to alarmingly increasing prevalence of the two
chronic conditions [7, 8]. A recent research estimated that
5.6% of all incident cancers in 2012, corresponding to
792,600 new cases, were attributable to the combined
effects of diabetes and high body mass index (BMI) [9]. As
two independent risk factors for overall and certain types
of cancer in general population, diabetes and obesity have
common biological mechanisms, such as insulin resistance
and hyperinsulinemia [10–13]. However, the nature of
type 2 diabetes (T2DM) may differ by BMI, a surrogate
marker of leanness/obesity. It is reported that patients
underweight or with normal weight may suffer from less
beta-cell dysfunction and insulin resistance than those
obese [14], while diabetic patients with higher BMI were
more likely to experience insulin resistance due to adipos-
ity [15]. T2DM and obesity were also observed to jointly
promote the development of certain subtypes of cancer,
but the results varied by cancer sites and across popula-
tions [16–18].
To evaluate the association of BMI with cancer risk
among T2DM patients is another approach to better un-
derstanding the mechanisms that link obesity and diabetes
with cancers. However, limited evidence is available on the
association between BMI and cancer risks in patients with
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T2DM [19, 20]. In this study, we conducted a large-scale
retrospective cohort study based on the diabetes manage-
ment database in Minhang district of Shanghai, China, to
examine the association between BMI and risks of overall
and site-specific cancers in Chinese diabetic patients.
Methods
Study population
This retrospective cohort study was a population-based
study based on a standardized management system of
diabetes in Shanghai, China. According to the Chinese
National Diabetes Prevention Guide, the standardized
management of diabetic patients has been carried out as
a basic community health service since 2004 in Minhang
district, an administrative area with 1,000,000 residents
of Shanghai, China [6, 21]. A total of 52,764 patients
were diagnosed with T2DM during the period from
2004 to 2014 based on the 1999 criteria of the World
Health Organization (WHO) [22]. All patients were
enrolled in this study and followed up until date of
cancer diagnosis, death, or September 30, 2015.
Data collection
Baseline information on demographic factors, diagnosis
date of diabetes, self-reported standing height and body
weight, and regular exercise was derived from the elec-
tronic health record (eHR) database. BMI was calculated
as body weight in kilogram divided by squared body
height in meters. A total of 1440 patients with any type of
cancer at the time of diagnosis of T2DM were excluded,
leaving 51,324 (24,124 men, 27,200 women) patients in
the study. Patients with incomplete data of BMI (n = 229)
and those diagnosed with cancer within three months of
T2DM diagnosis (n = 91) were further excluded. Finally,
51,004 patients (23,981 men and 27,023 women) were
included in the analysis.
Outcome of interest in this study was the incidence of
any primary cancers. The incident cancers and all-cause
deaths in the patients until September 30, 2015 were iden-
tified by linking with the Shanghai Cancer Registry and
the Shanghai Vital Statistics using a unique identification
card number [23, 24]. Cancer cases were ascertained
according to the International Classification of Diseases
(ICD-10) codes by the type of cancers such as Stomach
(C16), Colorectum (C18-C20), Pancreas (C25), Trachea,
bronchus and lung (C33-C34), Breast (C50), Prostate
(C61), Bladder (C67) and Thyroid (C73).
Statistical analysis
Person-year (PY) of follow-up was calculated from the date
of T2DM diagnosis to the date of diagnosis of primary
cancer, date of death, or the end of follow-up (September
30, 2015), whichever occurred first. Incidence rates were
calculated as the number of cancer cases divided by the
person-years of observation. Comparisons of demographic
characteristics and clinical and lifestyle factors across base-
line BMI categorized according to WHO classification [25]
were assessed using Kruskal-Wallis tests (for continuous
variables) or χ2 tests (for categorical variables). Log-rank
test was used to examine the difference of cancer incidence
across groups with different BMI levels.
Cox proportional hazard model was used to estimate the
associations between BMI and the risks of both overall and
cancer subtypes, adjusting for age at diagnosis of diabetes,
comorbidity of hypertension (Yes/No), and family history of
diabetes (Yes/No). Patients with unspecified family history
of diabetes were treated as a separate group in multivariate
analysis. Log-log survival plot was applied to evaluate the
proportional hazard assumption for BMI. The potential
curvilinear relationship of BMI with cancer risk was exam-
ined by utilizing restricted cubic splines (RCS) using the
5th, 50th and 95th percentiles as fixed knots [26, 27]. Two
statistical tests were conducted: one was to test the null hy-
pothesis that the regression coefficients of both linear and
non-linear terms of the factor were equal to zero, with the
result presented as “p for overall association”; another statis-
tical test was for the regression coefficient of nonlinear term
(i.e. spline variable), with “p for non-linearity” < 0.05 indicat-
ing a non-linear association. The nature of the relationships
was shown visually by figures. Multivariable adjusted hazard
ratios (HRs) and 95% confidence intervals (95% CIs) were
estimated by Cox regression model with RCS functions
using BMI values of 25 kg/m2 as reference for any other
values of BMI. All analyses were performed using SAS
(version 9.4; SAS Institute, Cary, NC). RCS was completed
by SAS macro %RCS [28]. All tests were two-sided and
p < 0.05 was considered as significant.
In sensitivity analysis, a novel E-value approach proposed
by VanderWeele and Ding was applied to estimate to what
extend unmeasured confounders could explain away the
observed association [29]. Moreover, the association
between BMI and overall cancer risk was compared with
or without the variable of smoking status in male with age
younger than 60 years old.
Results
Baseline characteristics of T2DM patients
Among newly-diagnosed T2DM patients (n = 51,004) with
average age of 61.3 years old, 23,981 (47.0%) were men
and 27,023 (53.0%) were women. After a total of 324,116
person-year of follow-up (150,646 in men and 173,190 in
women), 2764 cancer cases were identified through a
record-linkage with the Shanghai Cancer Registry System.
Table 1 shows the demographic characteristics and clin-
ical and lifestyle factors of T2DM patients by baseline BMI.
Significant differences were found for age at diagnosis of
T2DM, gender, family history of diabetes, pre-existing
hypertension, and regular exercise across BMI categories.
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Overall and site-specific cancer incidence across BMI
categories
As shown in Table 2, the incidence of overall cancer was
853.5/100,000 in all T2DM patients, 919.6/100,000 in men,
and 794.6/100,000 in women. The incidence was higher in
underweight (1140.3/100,000) or obese patients (879.6/
100,000) than in normal (847.2/100,000) or overweight
patients (842.4/100,000). This pattern was more evident in
men, among whom the incidence in both underweight
(1661.8/100,000) and overweight (871.0/100,000) patients
were higher comparing to both normal weight (955.8/
100,000) and obese (821.2/100,000) patients (p < 0.001).
The median follow-up time from T2DM diagnosis to can-
cer diagnosis was 4.28 and 4.27 years in men and women,
respectively.
Table 3 presents the incidence of several common cancer
types in diabetic patients by BMI categories. Colorectal
cancer ranked first in the number of cancer cases and inci-
dence, followed by trachea, bronchus and lung cancer,
stomach cancer, female breast cancer, and prostate cancer.
Non-linear associations of BMI with overall and site-specific
cancer incidence among T2DM patients
Figure 1 demonstrates the associations between BMI
and overall cancer risk in diabetes patients by sex and
age group (< 60 years and ≥60 years). BMI was significantly
related to the incidence of overall cancer in men with age
younger than 60 years old (p for overall association =
0.009). This association was in a non-linear pattern, with
an increased risk of overall cancer observed among patients
with either lower or higher BMI (p for non-linearity =
0.003). Compared with patients with BMI of 25.0 kg/m2,
those with BMI at the 1st percentile (near 18.0 kg/m2) had
a 74% increased risk (95% CI: 1.17–2.57) and those at the
99st percentile (near 32.0 kg/m2) had a 60% increased risk
(95% CI: 1.07–2.40). However, there was no similar associ-
ation in men older than 60 years old (p for overall associ-
ation = 0.749). In women, BMI was only significantly
related to the risk of overall cancer (p for overall associ-
ation =0.009) for those with age older than 60 years old
in a linear pattern (p for non-linearity = 0.249) as shown
in Fig. 2.
As shown in Fig. 3, no significant association was
observed between BMI and the risk of any subtype of com-
mon cancers like stomach, colorectal, pancreas, lung, blad-
der, and prostate cancer in men. Also, no significant
association was observed between BMI and cancers of
stomach, colorectal, lung, pancreas and thyroid in women.
However, a significant and linear association was observed
between BMI and the risk of breast cancer (p for overall
association = 0.033, p for non-linearity = 0.568). For women
older than 60 years old, each unit increase in BMI was
linked with a 3% (95%CI: 1–5%) increased risk of overall
cancer and a 7% (95%CI: 1–13%) increased risk for breast
Table 1 Demographic characteristics, clinical predictors and lifestyle factors in T2DM patients by baseline BMI
Characteristics BMI (WHO category, kg/m2) P values
< 18.5 (N = 1106) 18.5–24.9 (N = 29,764) 25.0–29.9 (N = 17,578) > 30.0 (N = 2556)
Diagnosis age of T2DM (x ± SD, yrs) 65.0 ± 12.6 61. 6 ± 11.1 60.6 ± 10.7 60.0 ± 11.2 < 0.001
< 60 years 395(35.71) 13,890(46.67) 8639(49.15) 1293(50.59) < 0.001
≥ 60 years 711(64.29) 15,874(53.33) 8939(50.85) 1263(49.41)
Follow-up time (years) 6.42 ± 3.17 6.42 ± 3.10 6.26 ± 3.07 6.05 ± 3.06 < 0.001
Gender (%)
Male 646(40.3) 14,078(47.3) 8473(48.2) 984(38.5) < 0.001
Female 660(59.7) 15,686(52.7) 9105(51.8) 1572(61.5)
Family history of DM (%)
Yes 237(21.4) 6727(22.6) 4254(24.2) 624(24.4) 0.014
No 695(62.8) 18,781(63.1) 11,127(63.3) 1608(62.9)
Unspecified 175(15.7) 4256(14.2) 2197(12.5) 325(12.7)
Pre-existing hypertension (%)
Yes 647(58.5) 19,859(66.7) 13,544(77.0) 2147(84.0) < 0.001
No 459(41.5) 9905(33.3) 4034(23.0) 409(16.0)
Regular exercise (%)
Yes 260(50.6) 17,918(60.2) 11,004(62.6) 1600(62.6) 0.16
No 296(26.8) 8513(28.6) 5062(28.8) 751(29.4)
Unspecified 250(22.6) 3334(11.3) 1512(8.6) 204(8)
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cancer (Table 4). A similar association pattern was
observed for overall and breast cancer when BMI was
treated as a categorical variable. Compared with normal
weight group (BMI =18.5–24.9 kg/m2), significant higher
risks of overall and breast cancer were observed in the
obese group (BMI ≥30.0 kg/m2).
Sensitivity analysis
According to the E-value approach, if the observed HR of
1.74 in male would be completely due to unmeasured
confounder, a 2.87-fold association between unmeasured
confounder and overall cancer risk would be required
(Fig. 1). Similarly, a 1.21-fold association between unmeas-
ured confounder and cancer risk would be needed to
explain away the observed linear dose response associ-
ation of BMI and overall cancer risk in female with age
older than 60 years old. The association between BMI and
overall cancer risk with or without adjusting for smoking
status remained unchanged in male younger than 60 years
old, as presented in Additional file 1: Figure S1.
Discussion
In this population-based retrospective cohort study, we
found that the associations between BMI and cancer
risks varied by gender, age groups (< 60 years old and
≥60 years old) and cancer subtypes among Chinese dia-
betic patients. In men with age younger than 60 years
old, the cancer risk increased with either lower or higher
Table 3 Incidence of common site-specific cancers in Chinese diabetes patients by baseline BMI
Subtypes of cancer ICD (10th) No. of cases Incidence
(1/100,000)
By BMI
< 18.5 18.5–24.9 25.0–29.9 > = 30 P values
No. of
cases
Incidence
(1/100,000)
No. of
cases
Incidence
(1/100,000)
No. of
cases
Incidence
(1/100,000)
No. of
cases
Incidence
(1/100,000)
Stomach C16 279 86.08 11 152.7 153 80.01 101 91.78 14 89.5 0.157
Colorectal C18-C20 451 139.15 10 138.8 266 139.1 148 134.49 27 172.61 0.645
Pancreas C25 137 42.27 3 41.63 87 45.5 41 37.26 6 38.36 0.758
Trachea, bronchus
& lung
C33–34 408 125.88 15 208.12 267 139.63 110 99.96 16 102.29 0.005
Breast a C50 258 79.6 5 69.36 139 72.69 92 83.6 22 140.65 0.129
Prostate b C61 129 39.8 3 41.61 74 38.7 49 44.53 3 19.18 0.711
Bladder b C67 57 17.59 3 69.33 28 16.73 22 26.35 4 25.57 0.114
Thyroid a C73 115 35.48 3 41.59 62 37.13 48 51.8 2 31.97 0.113
Others 930 286.93 28 394.17 544 284.48 316 287.15 42 271.64 0.404
a among women only; b among men only
Table 2 Cancer incidence by baseline BMI in T2DM patients
Characteristics BMI (WHO category, kg/m2) P values
< 18.5 (N = 1106) 18.5–24.9 (N = 29,764) 25.0–29.9 (N = 17,578) > 30.0 (N = 2556) Overall
All subjects
No. of Subjects 1106 29,764 17,578 2556 51,004
Person-years 7203.5 191,223.9 110,046.6 15,641.9 324,115.9
No. of cancer Cases 81 1620 927 136 2764
Incidence (per 100,000 person-years) 1140.3 847.2 842.4 879.6 853.5 0.069
Male
No. of Subjects 446 14,082 8468 985 23,981
Person-years 2948.6 89,664.6 52,242.8 5970.3 150,826.4
No. of cancer Cases 49 857 429 52 1387
Incidence (per 100,000 person-years) 1661.8 955.8 821.2 871 919.6 < 0.001
Female
No. of Subjects 660 15,682 9110 1571 27,023
Person-years 4255 101,559.3 57,803.7 9671.6 173,289.5
No. of cancer Cases 32 763 498 84 1377
Incidence (per 100,000 person-years) 752.1 751.3 861.5 868.5 794.6 0.073
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Fig. 1 HRs (95%CIs) between BMI (kg/m2) and the risk overall cancer in male T2DM patients by age subgroups, allowing for non-linear effects.
The reference BMI for these plots (with HR fixed as 1.0) was 25 kg/m2
Fig. 2 HRs (95%CIs) between BMI (kg/m2) and the risk overall cancer in female T2DM patients by by age subgroups, allowing for non-linear effects.
The reference BMI for these plots (with HR fixed as 1.0) was 25 kg/m2
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Fig. 3 HRs (95%CIs) of BMI (kg/m2) with the risk of common site-specific cancers in male (left) and female (right) T2DM patients, allowing for non-linear
effects. The reference BMI for these plots (with HR fixed as 1.0) was 25 kg/m2
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BMI comparing to those with BMI of 25.0 kg/m2. In
women with age older than 60 years old, a linear
dose-response relationship was observed between BMI
and the risk of both overall and breast cancer.
Obesity [1–4] and diabetes mellitus [5, 6] are two inde-
pendent risk factors for overall and certain types of cancer
in general population. In our previous study, comparing
to the local general population, diabetic patients had an
increased risk of overall cancer in both sexes, as well as
increased risks of colon, rectum, prostate, and bladder
cancers in men and increased colon, breast, and corpus
uteri cancer risks in women [6]. Several studies observed a
modifying effect of BMI on the association between
diabetes and cancer [15–18]. However, few studies have
evaluated the BMI-cancer association among T2DM
patients and the conclusion was inconsistent.
A register-based cohort study in Sweden has reported
that excess body weight was associated with increased
risks of all cancer, gastrointestinal cancer and colorectal
cancer in male T2DM patients and with elevated risks of
all cancer, gestational cancer and postmenopausal breast
cancer in female T2DM patients [20]. However, the study
did not include patients with BMI less than18.5 kg/m2. A
study based on the Japan National Center Diabetes
Database did not find a significant association between
BMI categories and the risk of overall cancers and
obesity-related cancers among male patients, but observed
a significantly higher risk of overall cancer among female
patients with BMI less than 22 kg/m2 [19].
We found that the association between BMI and
cancer in people with T2DM depend on sex-specific age
subgroups (< 60 years old and ≥60 years old). Due to the
application of RCS, nonlinear associations characterized
by increased risks of cancer in men with lower and higher
BMI was observed when comparing with those having
BMI of 25.0 kg/m2. The results were similar with the
results of the Sweden study but inconsistent with the
Japanese study. In women older than 60 years old, higher
BMI values were related to a higher overall cancer risk,
which was consistent with the study in Sweden, but
differed from the higher cancer risk that observed in
Japanese T2DM women with lower BMI. This controver-
sial association was likely due to the difference in source
population of the studies. Community population based
on eHR system was selected in our study, but hospital
population was recruited in the above mentioned Japanese
study. Moreover, ethnic background [4], different subtype
of cancers [16, 17], and relevant small sample size of the
Japanese study may also contribute to the discrepancy.
Regarding to cancer subtypes, a significant association
was observed only for breast cancer risk in female. Our
findings are somewhat supported by the results of the
Sweden study. The increased risk of breast in female with
age older than 60 years is also consistent with a previous
study conducted in the general population, in which obese
(BMI > 30 kg/m2) Chinese women had 36% increased risk
of overall cancer and 143% increased risk of postmeno-
pausal breast cancer compared to those with BMI of
18.5–22.9 kg/m2 [30]. The difference of BMI and the risk
of overall and breast cancer by the age group in female
may suggest the effect modification of menopause.
The World Cancer Research Fund reported that being
overweight or obese is related to an increased incidence
of stomach, colorectal, pancreatic and kidney cancer in
both men and women, as well as an elevated risk of
advanced prostate cancer in men [31]. For lung cancer,
Table 4 The association of BMI with the risk of selected subtypes of cancer in T2DM patients
Gender subtypes of cancer Categories of BMI < 60 years old > 60 years old
No. of cancer cases HR 95%CI No. of cancer cases HR 95%CI
Male All sites of cancer < 18.5 11 1.42 0.78–2.61 38 1.21 0.87–1.68
18.5–24.9 241 1(ref) 616 1(ref)
25.0–29.9 128 0.89 0.72–1.11 301 0.98 0.86–1.13
≥30.0 23 1.4 0.91–2.15 29 0.98 0.68–1.43
Female All sites of cancer BMI as a continuous variable non-linearity 833 1.03 1.01–1.05
< 18.5 9 0.95 0.49–1.85 23 0.9 0.59–1.36
18.5–24.9 295 1(ref) 468 1(ref)
25.0–29.9 214 1.22 1.02–1.46 284 1.15 0.99–1.33
≥30.0 26 0.86 0.58–1.29 58 1.44 1.10–1.90
Breast cancer BMI as a continuous variable non-linearity 123 1.07 1.01–1.13
< 18.5 1 0.40 0.06–2.90 4 1.38 0.50–3.82
18.5–24.9 78 1(ref) 61 1(ref)
25.0–29.9 46 0.96 0.67–1.39 46 1.36 0.93–2.00
≥30.0 10 1.2 0.62–2.33 12 2.19 1.18–4.07
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increasing BMI is a protective factor [32]. Different
proportion of obesity-related and non-obesity-related can-
cers in both sexes may contribute to the different
association between BMI and the overall cancer risk.
However, we did not observe a significant association of
BMI with any of these site-specific cancers. The moderate
sample size and small number of site-specific cancer cases
may lead to limited power for estimating these
associations. Ethnicity may also explain the difference of
obesity effect between our study and other studies. A posi-
tive association of BMI was observed with rectum cancer
in European and Australian populations and with pancre-
atic cancer in North American, but not in Asia-Pacific
populations [4]. Further studies are warranted to confirm
the observed null associations between BMI and the risk
of cancer subtypes observed in our study .
Smoking status may be a potential confounder or an
effect modifier. Because about 70% of subjects were also
diagnosed with hypertension, we collected smoking infor-
mation through their hypertension file. For these subjects,
the smoking rate for women was only 0.85%. It was un-
likely that smoking status biased our estimated association
between BMI and cancer in women. The smoking rate for
men was about 40%. However, sensitivity analysis sug-
gested that smoking may not be a confounding factor in
this study. For other unmeasured confounders, sensitivity
analysis with E-value was applied to assess the robustness
of the observed association. Even though we do not have
these measurements, it is unlikely that these variables
would have an effect on cancer risks strong enough to
explain away the observed association.
Obesity and type 2 diabetes are closely associated with
metabolic abnormalities and poor glycemic control [33, 34]
that may contribute to cancer progression [35]. However,
the potential mechanisms of obesity, diabetes, and cancer
are not yet clear. Many possible explanations have been
proposed for certain cancers: The change of hormonal sys-
tem in insulin, insulin like growth factors, estrogens and
other cytokines could be induced by diabetic condition,
which may affect the breast cancer risk; the increased pro-
duction of leptin and the decreased production of adipo-
nectin caused by both obesity and T2DM may cause
similar risks for breast cancer [15]. Obesity is being increas-
ingly recognized as sub-clinical inflammation and accord-
ingly contributes to the increase of adipose tissue
infiltration of inflammatory components including
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α)
and C-reactive protein (CRP), all of which have shown to
be associated with the development of breast cancer eti-
ology [36]. Other possible mechanisms being explored in-
clude the contribution of lipids to cancer development and
metabolism, the role of the insulin receptor signaling in
cancer, the composition of advanced glycation end prod-
ucts, the changes in hormonal systems to female malignant
tumor and growth-promoting effects of obesity and type 2
diabetes on different site-specific cancers. Therefore, the
mechanisms underlying the associations between obesity
and cancers in diabetic patients are complex and
heterogeneous.
The strengths of this study include the retrospective co-
hort study design, relatively large sample size (n = 51,004),
and ability to assess associations wih specific cancer sites.
Cox proportional hazard models with restricted cubic
spline functions help to test potential non-linear relation-
ship with high statistical power. Stratified analysis by sex
and age groups enables us to examine the possible differ-
ence in sex-specific associations between BMI and overall
cancer risk by removing the confounding effect of age.
However, several limitations should be mentioned. First,
BMI at diagnosis of T2DM may have been affected by the
actual duration of diabetes, which is difficult to acquire.
Second, self-reported BMI values were used in this study
and the number of subjects with BMI < 18.5 kg/m2 or
BMI > 30 kg/m2 was not enough to have a stable estima-
tion of associations. Third, we did not include information
on waist circumference, percentage of body fat, level of
blood sugar, or the intake of medications such as metfor-
min, making it impossible to evaluate the potential effect
of these variables on the risk of cancer in diabetic patients.
Finally, although smoking status was less likely to bias the
results, the study could not provide an estimated measure
of BMI and cancer risk adjusted for smoking.
Conclusions
In this population-based retrospective cohort study, we
found that the associations of BMI with the overall cancer
risk varied by gender, age subgroups (< 60 years old and
≥60 years old) and cancer subtypes among Chinese dia-
betic patients. This indicates complex and heterogeneous
biological mechanisms. Increased risks in younger male
patients with either lower or higher BMI and in obese
older female patients imply that cancer prevention should
be focused on these populations.
Additional file
Additional file 1: Figure S1. HRs (95%CIs) between BMI (kg/m2) and
the risk overall cancer in male T2DM patients with age younger than
60 years, and pre-existing hypertension allowing for non-linear effects.
The shape of the association between BMI and overall cancer risk was
compared with or without the variable of smoking status in male with
Pre-existing hypertension, and age younger than 60 years old. The
reference BMI for these plots (with HR fixed as 1.0) was 25 kg/m2. Left:
No adjustment for smoking; Right: Adjustment for smoking; (the effect of
smoking after controlling for other variables, p = 0.064). (DOCX 197 kb)
Abbreviations
95% CIs: 95% confidence intervals; BMI: Body mass index; EHR: Electronic
health record; HRs: Hazard ratios; ICD: International classification of diseases;
PY: Person-year; RCS: Restricted cubic splines; T2DM: Type 2 diabetes mellitus
Xu et al. BMC Cancer  (2018) 18:795 Page 8 of 10
Acknowledgements
We are grateful to Shanghai population-based cancer registries for data
collection, sorting, verification.
Funding
The study was supported by a grant from National Nature Science
Foundation of China (No. 11371100); grant from Shanghai Municipal
Commission of Health and Family Planning (Grant No. 201640254); and
Nature Science Foundation of Minhang district, Shanghai, China (Grant
No. 2016MHZ25). The funding contributors had no role in the design of the
study, collection, analysis, or interpretation of the data, or writing of the
manuscript.
Availability of data and materials
The datasets generated and analyzed in the study are not publicly available
but are available from the corresponding authors on reasonable request.
Authors’ contributions
All of the authors met the ICMJE recommendations for authorship. GYQ and
HLX contributed to the study design; HLX and MLZ conducted data analysis.
HLX, QG, YJY, and FZ contributed to the first script of the manuscript; WHX,
DLX and NQZ contributed to the interpretation of results; WHX ZFZ and FF
revised the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This cohort study used anonymised data from local Diabetes Patient
Management System and Cancer Registry, and had approval from the
Institutional Review Board of Minhang Center for Disease Control and
Prevention (NO: EC-P-2012-002).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1School of Public Health, Fudan University, 138 Yi Xue Yuan Road, Shanghai
200032, People’s Republic of China. 2Shanghai Minhang Center for Disease
Control and Prevention, 965 Zhong Yi Road, Shanghai 201101, People’s
Republic of China. 3Department of Epidemiology, UCLA Fielding School of
Public Health, Los Angeles, CA, USA. 4Shanghai Municipal Center for Disease
Control and Prevention, 1380 West Zhong Shan Road, Shanghai 200336,
People’s Republic of China. 5Key Laboratory of Public Health Safety, Fudan
University, Shanghai, People’s Republic of China. 6Collaborative Innovation
Center of Social Risks Governance in Health, Fudan University, Shanghai,
People’s Republic of China.
Received: 28 February 2018 Accepted: 18 July 2018
References
1. Bhaskaran K, Douglas I, Forbes H, Dos-Santos-Silva I, Leon DA, Smeeth L.
Body-mass index and risk of 22 specific cancers: a population-based cohort
study of 5.24 million UK adults. LANCET. 2014;384(9945):755–65.
2. Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, Diem G,
Oberaigner W, Weiland SK. Obesity and incidence of cancer: a large cohort
study of over 145,000 adults in Austria. Br J Cancer. 2005;93(9):1062–7.
3. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and
mortality in relation to body mass index in the million women study:
cohort study. BMJ. 2007;335(7630):1134.
4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index
and incidence of cancer: a systematic review and meta-analysis of
prospective observational studies. LANCET. 2008;371(9612):569–78.
5. Lin CC, Chiang JH, Li CI, Liu CS, Lin WY, Hsieh TF, Li TC. Cancer risks among
patients with type 2 diabetes: a 10-year follow-up study of a nationwide
population-based cohort in Taiwan. BMC Cancer. 2014;14:381.
6. Xu HL, Fang H, Xu WH, Qin GY, Yan YJ, Yao BD, Zhao NQ, Liu YN, Zhang F,
Li WX, et al. Cancer incidence in patients with type 2 diabetes mellitus: a
population-based cohort study in shanghai. BMC Cancer. 2015;15:852.
7. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in
obesity among US adults, 1999-2008. JAMA. 2010;303(3):235–41.
8. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, et al.
Prevalence of diabetes among men and women in China. N Engl J Med.
2010;362(12):1090–101.
9. Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide
burden of cancer attributable to diabetes and high body-mass index: a
comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(2):95–104.
10. Kasuga M, Ueki K, Tajima N, Noda M, Ohashi K, Noto H, Goto A, Ogawa W,
Sakai R, Tsugane S, et al. Report of the Japan diabetes society/Japanese
Cancer association joint committee on diabetes and Cancer. Cancer Sci.
2013;104(7):965–76.
11. Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of Cancer
and Cancer-related mortality. Physiol Rev. 2015;95(3):727–48.
12. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Plasma C-peptide,
insulin-like growth factor-I, insulin-like growth factor binding proteins and
risk of colorectal cancer in a nested case-control study: the Japan public
health center-based prospective study. Int J Cancer. 2007;120(9):2007–12.
13. Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, Barker
A, Perry JR, Attia J, Dunning AM, et al. Evidence of a Causal Association
Between Insulinemia and Endometrial Cancer: A Mendelian Randomization
Analysis. J Natl Cancer Inst. 2015;107(9):djv178.
14. Kuroe A, Fukushima M, Usami M, Ikeda M, Nakai Y, Taniguchi A, Matsuura T,
Suzuki H, Kurose T, Yasuda K, et al. Impaired beta-cell function and insulin
sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res
Clin Pract. 2003;59(1):71–7.
15. Alokail MS, Al-Daghri NM, Al-Attas OS, Hussain T. Combined effects of
obesity and type 2 diabetes contribute to increased breast cancer risk in
premenopausal women. Cardiovasc Diabetol. 2009;8:33.
16. Moe B, Nilsen TI. Cancer risk in people with diabetes: does physical activity
and adiposity modify the association? Prospective data from the HUNT
study Norway. J Diabetes Complications. 2015;29(2):176–9.
17. Seow A, Yuan JM, Koh WP, Lee HP, Yu MC. Diabetes mellitus and risk of
colorectal cancer in the Singapore Chinese health study. J Natl Cancer Inst.
2006;98(2):135–8.
18. Choi JB, Moon HW, Park YH, Bae WJ, Cho HJ, Hong SH, Lee JY, Kim SW, Han
KD, Ha US. The impact of diabetes on the risk of prostate Cancer
development according to body mass index: a 10-year Nationwide cohort
study. J Cancer. 2016;7(14):2061–6.
19. Yamamoto-Honda R, Takahashi Y, Yoshida Y, Kwazu S, Iwamoto Y, Kajio H,
Yanai H, Mishima S, Shimbo T, Noda M. Body mass index and the risk of
cancer incidence in patients with type 2 diabetes in Japan: results from the
National Center Diabetes Database. J Diabetes Investig. 2016;7(6):908–14.
20. Miao JJ, Cederholm J, Gudbjornsdottir S. Excess body weight and cancer
risk in patients with type 2 diabetes who were registered in Swedish
National Diabetes Register--register-based cohort study in Sweden. PLoS
One. 2014;9(9):e105868.
21. Xu D, Fang H, Xu W, Yan Y, Liu Y, Yao B. Fasting plasma glucose variability
and all-cause mortality among type 2 diabetes patients: a dynamic cohort
study in shanghai China. Sci Rep. 2016;6:39633.
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes
mellitus and its complications. Part 1: diagnosis and classification of
diabetes mellitus provisional report of a WHO consultation. Diabet Med.
1998;15(7):539–53.
23. Xiang YB, Jin F, Gao YT. Cancer survival in shanghai, China 1992-1995. IARC
Sci Publ. 2011;162:55–68.
24. Xie SH, Chen J, Zhang B, Wang F, Li SS, Xie CH, Tse LA, Cheng JQ. Time
trends and age-period-cohort analyses on incidence rates of thyroid cancer
in shanghai and Hong Kong. BMC Cancer. 2014;14:975.
25. Obesity: preventing and managing the global epidemic. Report of a WHO
consultation. World Health Organ Tech Rep Ser. 2000;894:1–253.
26. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic
spline functions in public health research. Stat Med. 2010;29(9):1037–57.
27. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat
Med. 1989;8(5):551–61.
28. Heinzl H, Kaider A. Gaining more flexibility in cox proportional hazards
regression models with cubic spline functions. Comput Methods Prog
Biomed. 1997;54(3):201–8.
Xu et al. BMC Cancer  (2018) 18:795 Page 9 of 10
29. VanderWeele TJ, Ding P. Sensitivity analysis in observational research:
introducing the E-value. Ann Intern Med. 2017;167(4):268–74.
30. Liu Y, Warren AS, Wen W, Gao YT, Lan Q, Rothman N, Ji BT, Yang G, Xiang
YB, Shu XO, et al. Prospective cohort study of general and central obesity,
weight change trajectory and risk of major cancers among Chinese women.
Int J Cancer. 2016;139(7):1461–70.
31. Hendriks SH, Schrijnders D, van Hateren KJ, Groenier KH, Siesling S, Maas A,
Landman G, Bilo H, Kleefstra N. Association between body mass index and
obesity-related cancer risk in men and women with type 2 diabetes in primary
care in the Netherlands: a cohort study (ZODIAC-56). BMJ Open. 2018;8(1):e18859.
32. Duan P, Hu C, Quan C, Yi X, Zhou W, Yuan M, Yu T, Kourouma A, Yang K.
Body mass index and risk of lung cancer: systematic review and dose-
response meta-analysis. Sci Rep. 2015;5:16938.
33. El-Kebbi IM, Cook CB, Ziemer DC, Miller CD, Gallina DL, Phillips LS. Association
of younger age with poor glycemic control and obesity in urban african
americans with type 2 diabetes. Arch Intern Med. 2003;163(1):69–75.
34. Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and
diabetes in a US adult population: findings from the National Health and
nutrition examination survey, 1999-2006. Obes Surg. 2011;21(3):351–5.
35. Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, Bacon L, Rivera D, Urzua L,
Aguila C, Ramirez-Morales R, Santamaria J, Bargallo E, et al. Impact of
diabetes and hyperglycemia on survival in advanced breast cancer patients.
Exp Diabetes Res. 2012;2012:732027.
36. Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdogan M, Artac M,
Altunbas H, Akan I, Savas B. Tumour necrosis factor-alpha, interleukin-6, and
fasting serum insulin correlate with clinical outcome in metastatic breast
cancer patients treated with chemotherapy. CYTOKINE. 2004;27(2–3):58–65.
Xu et al. BMC Cancer  (2018) 18:795 Page 10 of 10
